Ameloblastic carcinoma: a multicenter Nigerian study.
| dc.contributor.author | Ndukwe, K.C. | |
| dc.contributor.author | Adebiyi, E.K. | |
| dc.contributor.author | Ugboko, V.I. | |
| dc.contributor.author | Ladeinde, A.L. | |
| dc.contributor.author | Okojie, V.N. | |
| dc.contributor.author | Ajike, S.O. | |
| dc.contributor.author | Olasoji, H.O. | |
| dc.date.accessioned | 2019-10-23T10:34:53Z | |
| dc.date.available | 2019-10-23T10:34:53Z | |
| dc.date.issued | 2010-09-01 | |
| dc.description.abstract | PURPOSE: To obtain a national profile on the prevalence and management of ameloblastic carcinoma in Nigerians. MATERIALS AND METHODS: Data were collected from the case files of patients with a histologic diagnosis of ameloblastic carcinoma from 4 tertiary referral centers in Nigeria from January 1980 to December 2008. RESULTS: Twenty patients were seen within the study period. There were 11 male and 9 female patients, with a male-to-female ratio of 1.2:1. Their ages ranged from 16 to 85 years (mean +/- SD, 41.63 +/- 19.8 years). The duration of the lesion before presentation was 6 months to 4 years. Twelve cases occurred in the posterior mandible alone, 1 case occurred in the anterior mandible alone, and 4 cases involved the anterior and posterior mandible. The posterior part of the maxilla was involved in 3 cases. A majority of the cases (17) occurred de novo, and 3 patients presented with carcinoma ex-ameloblastoma. Treatment included surgical resection with or without neck dissection. Eight patients declined treatment after diagnosis. Surgery was planned for 12 patients, but 2 patients died of intractable bleeding episodes before surgery. Mandibulectomies and maxillectomies were performed for 10 patients. Follow-up was carried out for 5 patients. Recurrence ranged from 6 to 96 months after the first surgery. Overall deaths recorded involved 6 patients. Three patients died within 3 years after the initial surgery and 1 patient died about 8 years after the initial surgery. One patient is still alive and well 1 year after surgery. CONCLUSION: Ameloblastic carcinoma is an uncommon malignancy. Most cases occur in the mandible and arise de novo. Early diagnosis and radical local excision remain the mainstay of treatment. | en_US |
| dc.identifier.citation | Ndukwe KC, Adebiyi EK, Ugboko VI, Adeyemo WL, Ajayi FO, Ladeinde AL, Okojie VN, Ajike SO, Olasoji HO. Ameloblastic carcinoma: a multicenter Nigerian study. J Oral Maxillofac Surg. 2010 Sep;68(9):2111-4. | en_US |
| dc.identifier.uri | https://ir.unilag.edu.ng/handle/123456789/6458 | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.subject | Ameloblastic carcinoma | en_US |
| dc.subject | Nigerians | en_US |
| dc.title | Ameloblastic carcinoma: a multicenter Nigerian study. | en_US |
| dc.type | Article | en_US |